HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

libenzapril

structure given in first source

Also Known As:

CGS 16617; CGS-16617; 1H-1-Benzazepine-1-acetic acid, 3-((5-amino-1-carboxypentyl)amino)-2,3,4,5-tetrahydro-2-oxo-

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - libenzapril: 5

Related Diseases

1.	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/01/1988 - "Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat." 01/01/1988 - "The present study was designed to examine the effects of two new angiotensin-converting enzyme (ACE) inhibitors, CGS 14831 and CGS 16617 (3 mg/kg i. v. 1 min prior to occlusion and 4 and 24 h after occlusion), on myocardial ischemic (MI) damage and left-ventricular hypertrophy in rats. "
2.	Hypertension (High Blood Pressure) 01/01/1993 - "A previous communication from this laboratory reported that brain uptake of libenzapril, a small polar molecule, was enhanced in chronic hypertension (1). " 02/01/1992 - "Effect of chronic hypertension on the blood-brain barrier permeability of libenzapril."
3.	Hemorrhagic Shock 07/01/1987 - "The effect of a specific inhibitor of thromboxane (Tx) A2 synthesis, CGS-13080, a new angiotensin converting enzyme inhibitor, CGS-16617, and a combination of both drugs was studied in hemorrhagic shock in rats. "
4.	Shock 07/01/1987 - "CGS-16617 (1 microgram/kg) attenuated significantly the pressor response to angiotensin I throughout the shock period. "
5.	Myocardial Infarction 07/01/1987 - "A specific inhibitor of thromboxane A2 (TxA2) synthesis, CGS-12970, a new angiotensin-converting enzyme (ACE) inhibitor, CGS-16617, and a combination of both agents were evaluated for their ability to reduce the extension of myocardial infarct size in rats. "

Related Drugs and Biologics

1.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
2.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3.	benazeprilat
4.	Thromboxanes
5.	Thromboxane A2 (A2, Thromboxane)
6.	Cathepsin D
7.	Angiotensin I
8.	3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid
9.	pirmagrel